310 related articles for article (PubMed ID: 22867718)
1. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Watson M; Lowy DR; Markowitz LE
Vaccine; 2012 Sep; 30(42):6016-9. PubMed ID: 22867718
[TBL] [Abstract][Full Text] [Related]
2. Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States.
Clay PA; Thompson TD; Markowitz LE; Ekwueme DU; Saraiya M; Chesson HW
Vaccine; 2023 Mar; 41(14):2376-2381. PubMed ID: 36907737
[TBL] [Abstract][Full Text] [Related]
3. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
Insinga RP; Dasbach EJ; Elbasha EH
Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates.
Ong KJ; Checchi M; Burns L; Pavitt C; Postma MJ; Jit M
Sex Transm Infect; 2019 Feb; 95(1):28-35. PubMed ID: 30674687
[TBL] [Abstract][Full Text] [Related]
5. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
7. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
Thomas TL
Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
[TBL] [Abstract][Full Text] [Related]
8. The healthcare costs of treating human papillomavirus-related cancers in Norway.
Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
[TBL] [Abstract][Full Text] [Related]
9. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
Goldstone SE; Vuocolo S
Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023
[TBL] [Abstract][Full Text] [Related]
10. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
11. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
[TBL] [Abstract][Full Text] [Related]
12. The economic burden of noncervical human papillomavirus disease in the United States.
Hu D; Goldie S
Am J Obstet Gynecol; 2008 May; 198(5):500.e1-7. PubMed ID: 18455524
[TBL] [Abstract][Full Text] [Related]
13. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
[TBL] [Abstract][Full Text] [Related]
14. The Estimated Lifetime Medical Cost of Diseases Attributable to Human Papillomavirus Infections Acquired in 2018.
Chesson HW; Laprise JF; Brisson M; Martin D; Ekwueme DU; Markowitz LE
Sex Transm Dis; 2021 Apr; 48(4):278-284. PubMed ID: 33492104
[TBL] [Abstract][Full Text] [Related]
15. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
16. [The disease burden of human papillomavirus in men is substantial and can potentially be prevented].
Kiellberg Larsen H; Kofoed K; Sand C
Ugeskr Laeger; 2013 Feb; 175(6):349-53. PubMed ID: 23402241
[TBL] [Abstract][Full Text] [Related]
17. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
[TBL] [Abstract][Full Text] [Related]
18. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
Ginindza TG; Sartorius B; Dlamini X; Östensson E
PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
[TBL] [Abstract][Full Text] [Related]
19. Reducing the health burden of HPV infection through vaccination.
Soper D
Infect Dis Obstet Gynecol; 2006; 2006 Suppl():83084. PubMed ID: 16967913
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive control of human papillomavirus infections and related diseases.
Bosch FX; Broker TR; Forman D; Moscicki AB; Gillison ML; Doorbar J; Stern PL; Stanley M; Arbyn M; Poljak M; Cuzick J; Castle PE; Schiller JT; Markowitz LE; Fisher WA; Canfell K; Denny LA; Franco EL; Steben M; Kane MA; Schiffman M; Meijer CJ; Sankaranarayanan R; Castellsagué X; Kim JJ; Brotons M; Alemany L; Albero G; Diaz M; de Sanjosé S;
Vaccine; 2013 Dec; 31 Suppl 5():F1-31. PubMed ID: 24331745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]